About Leucine-rich repeat-containing protein 74A
Leucine-rich repeat-containing protein 74A (LRRC74A) is a protein
from Homo sapiens identified by UniProt accession
Q0VAA2, 488 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Leucine-rich repeat-containing protein 74A |
| UniProt accession | Q0VAA2 |
| Gene | LRRC74A |
| Organism | Homo sapiens |
| Length | 488 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (8)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.42
- cervical cancer · score 0.09
- atrial fibrillation · score 0.06
- total blood protein measurement · score 0.04
- blood protein measurement · score 0.04
- urate measurement · score 0.04
- bone density · score 0.04
- protein measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q0VAA2-F1 | alphafold | PREDICTED | 83.67 | — |
Amino-acid sequence (488 residues)
MHIQFPSKPT LPRACWEGRI TAGSPGMPPD EIEIEPVRQS SDKMLYCEAE SPPTVEKVKP ARENSETDLE IEDDEKFFTT GQKELYLEAC KLMGVVPVSY FIRNMEESYV NLNHHGLGPR GTKAIAIALV SNMAVTKLEL EDNCIMEEGV LSLVEMLQEN YYLQEMNISN NHLGLEGARI ISDFFERNSS SIWSLELSGN DFKEDSAALL CQALSTNYQI KKLDLSHNQF SDVGGEHLGQ MLAINVGLTS LDLSWNNFHT RGAVALCNGL RGNVTLTKLD LSMNGFGNEV ALALGEVLRL NRCLVYLDIG GNDIGNEGAS KISKGLESNE SLRVLKLFLN PINMDGAILL ILAIKRNPKS RMEELDISNV LVSEQFMKTL DGVYAVHPQL DVVFKAVQGL SPKKTIFLLT NPMKLIQSYA DQHKITIVDF FKSLNPTGTM KMSVDEFQKV MIEQNKVPLN QYQVREVIKK LDEKTGMVNF SFLNTMKP
Explore Leucine-rich repeat-containing protein 74A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets